Good afternoon everyone. I’m very pleased to have Momenta here with us today. Thanks for taking the time and sticking around for this last presentation it’s going to be an interesting one because this is a really interesting company in the generic pharmaceuticals space. For those of you who that don’t know me I’m Sumant Kulkarni and I’m part of the specialty pharmaceuticals in U.S. major pharmaceuticals team here at the firm. So we have Rick Shea, who is the CFO and who is back with us this year and Lora Pike, who is with us for the first time this year is the IR for Momenta. Thanks.

Richard P. Shea

Thanks very much Sumant. I will draw your attention to our risk factors particularly as included within our SEC filings. Momenta was founded and built based on analytical technologies for deconvolution and characterizing complex mixture drugs and these complex mixture drugs include polysaccharides heparin based drugs, polypeptides as well as biologics which includes glycosylated proteins and antibodies and technology that we use is by understanding the drug and understanding the chemical structure of the drug we are able to analyze and recreate exact copies of a complex drug in order to make a generic version or a biosimilar version. But we are also able to do structure activity relationship analysis and whether to understand how to engineer novel drugs based on this technology.